Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dordaviprone SCHEMBL16227974 | 1.00 | CLPP (1.00) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| Dordaviprone SCHEMBL29414943 | 0.99 | CLPP (0.98) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| Dordaviprone SCHEMBL31548590 | 0.99 | CLPP (0.98) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL20173633 | 0.94 | CLPP (0.89) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL18254991 | 0.94 | CLPP (0.89) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL26265189 | 0.93 | CLPP (0.88) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL19222684 | 0.93 | CLPP (0.88) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL13559495 | 0.93 | CYP3A4 (1.00) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL30085760 | 0.93 | CYP3A4 (1.00) | CLPPCYP3A4GPR132CYP2D6DRD2 | |
| SCHEMBL18254945 | 0.92 | CLPP (0.85) | CLPPCYP3A4GPR132CYP2D6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 762 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081496-A | Combined pharmaceutical composition for tumor treatment, application thereof and application of mitochondrial biosynthesis genes as biomarkers in tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070919-A | New application of ClpP agonist | 四川大学 | 2026-05-22 | — | — | CN | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4698146-A1 | LIQUID AND SOLID COMPOSITIONS OF IMIPRIDONE DERIVATIVES | Institut Gustave-Roussy (FR) | 2026-02-25 | — | — | EP | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250339680-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2025-11-06 | — | — | US | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-114669977-A | New crown vaccine film-coated bottle stopper vulcanization mold and manufacturing method | 湖北华强科技股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| WO-2022130384-A1 | CONTROLLING UBIQUITINATION OF MLKL FOR TREATMENT OF DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-06-23 | — | — | WO | claimed |
| US-20220143024-A1 | METHODS OF USING IMIPRIDONES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | US | claimed |
| US-11319376-B2 | Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer | REMD BIOTHERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| WO-2022082078-A1 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| US-20220098580-A9 | MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLS | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2022-03-31 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | CLPP 1572/4885CYP3A4 4325/4885GPR132 4412/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | CLPP 3399/4885CYP3A4 4006/4885GPR132 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.